Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,738
datasets available to search
ShareScore release 0.9.0
Dataset results
2,738 results for “multiple sclerosis”
When 'good' is not good enough: a retrospective Rasch analysis study of the Berg Balance Scale for persons with Multiple Sclerosis
<p>Raw data associated with the scientific publication "When ‘good’ is not good enough: a retrospective Rasch analysis study of the Berg Balance Scale for persons with Multiple Sclerosis".</p>
Fig. 2 in Triterpene glycosides from Blighia welwitschii and evaluation of their antibody recognition capacity in multiple sclerosis
Fig. 2. Data distribution of IgM antibody responses to saponins 2, 6, 7, hederagenin monodesmoside and giganteaside J from B. welwitschii, in MS patients' sera, determined by ELISA. CSF114(Glc) and its unglucosylated analogue, CSF114, were tested as positive and negative controls, respectively. Glc oleanolate from O. obtusifolia, whose glycoside part is significantly different from B. welwitschii saponins, was tested as a reference compound. Data are reported as absorbance at 405 nm of sera diluted 1:100. Horizontal lines represent mean values with their SD. Mann-Witney U test showed that the CSF114(Glc) distribution significantly differs from this of CSF114 (p value <0.0001, two-tailed). Kruskal-Wallis test including multiple comparison of natural glycosides distributions showed statistical differences between compound 2 and 6 (p value <0.05), 2 and 7 (p value <0.0001), 2 and hederagenin monodesmoside (p value <0.01), Glc oleanolate and hederagenin monodesmoside (p value <0.05), Glc oleanolate and 7 (p value <0.0001) and Glc oleanolate and 6 (p value <0.05).
Fig. 3 in Triterpene glycosides from Blighia welwitschii and evaluation of their antibody recognition capacity in multiple sclerosis
Fig. 3. Data distribution of IgM antibody responses to saponins 2, 6, 7, hederagenin monodesmoside and giganteaside J from B. welwitschii as well as Glc oleanolate from O. obtusifolia, in the sera of multiple sclerosis (MS) and ctrl patients, determined by ELISA. CSF114(Glc) and the unglucosylated peptide CSF114 were tested as controls. Data are reported as absorbance at 405 nm of sera diluted 1:100. Horizontal lines represent mean values with their SD. MannWitney U test showed that MS and ctrl distributions significantly differ for CSF114(Glc), CSF114 (p value <0.0001, two-tailed) and for Glc oleanolate (p value <0.05, two-tailed). In contrast, saponins 2, 6, 7, hederagenin monodesmoside and giganteaside J did not show any statistical differences between the two sera distributions (p value> 0.05, two-tailed).
Single nuclei RNAseq stratifies multiple sclerosis patients into distinct white matter glial responses
<p>The lack of understanding of the cellular and molecular basis of clinical and genetic heterogeneity in progressive multiple sclerosis (MS) has hindered the search for new effective therapies. Here, to address this gap, we analysed 632,000 single nuclei RNAseq profiles of 156 brain tissue samples, comprising white matter (WM) lesions, normal appearing WM, grey matter (GM) lesions and normal appearing GM from 54 MS patients and 26 controls. We observed the expected changes in overall neuronal and glial numbers previously described within the classical lesion subtypes. We found highly cell type-specific gene expression changes in MS tissue, with distinct differences between GM and WM areas, confirming different pathologies. However, surprisingly, we did not observe distinct gene expression signatures for the classical different WM lesion types, rather a continuum of change. This indicates that classical lesion characterization better reflects changes in cell abundance than changes in cell type gene expression, and indicates a global disease effect. Furthermore, the major biological determinants of variability in gene expression in MS WM samples relate to individual patient effects, rather than to lesion types or other metadata. We identify four subgroups of MS patients with distinct WM glial gene expression signatures and patterns of oligodendrocyte stress and/or maturation, suggestive of engagement of different pathological processes, with an additional more variable regenerative astrocyte signature. The discovery of these patterns, which were also found in an independent MS patient cohort, provides a framework to use molecular biomarkers to stratify patients for optimal therapeutic approaches for progressive MS, significantly advances our mechanistic understanding of progressive MS, and highlights the need for precision-medicine approaches to address heterogeneity among MS patients.</p>
Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis
ClinicalTrials.gov study NCT06569550. IPD Sharing: NO. Countries: 1. Publications: 0.
Muscle Architecture of Lower Extremity In Multiple Sclerosis
ClinicalTrials.gov study NCT03766698. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Upper Limbs Intervention in Multiple Sclerosis
ClinicalTrials.gov study NCT02047825. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation
ClinicalTrials.gov study NCT01758224. IPD Sharing: NO. Countries: 1. Publications: 2.
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01701856. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT05029830. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Upper Extremity Function, Shoulder Position Sense and Disability Level İn Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT03846336. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor
ClinicalTrials.gov study NCT00095329. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Olfactory and Trigeminal Functions in Patients With Multiple Sclerosis: Case-control Study
ClinicalTrials.gov study NCT06020937. IPD Sharing: UNDECIDED. Countries: 1. Publications: 14.
The Effect of Nurse Practitioner (NP-led) Care Upon Mood in People With Multiple Sclerosis
ClinicalTrials.gov study NCT04388592. IPD Sharing: NO. Countries: 1. Publications: 29.
Dual-Task Performance in Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT03508284. IPD Sharing: NO. Countries: 1. Publications: 16.
Clinical Factors Associated With Position Sense in Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT04548297. IPD Sharing: UNDECIDED. Countries: 1. Publications: 5.
High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
ClinicalTrials.gov study NCT01679041. IPD Sharing: Not stated. Countries: 1. Publications: 12.
E-Based Physical Exercise in Patients With Multiple Sclerosis and Comorbidity
ClinicalTrials.gov study NCT06298201. IPD Sharing: NO. Countries: 1. Publications: 0.
KITAMS: Kinesio Tape and Physical Function in Persons With Multiples Sclerosis
ClinicalTrials.gov study NCT03804047. IPD Sharing: NO. Countries: 1. Publications: 22.
Dalfampridine in Egyptian Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT05730738. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.